A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

NCT02724254 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Condyloma

Interventions

DRUG: AP611074 5% gel
DRUG: AP611074 matching placebo

Sponsor

Vaxart